

China supports global polio endgame strategy with new vaccine

19 July 2021 | News

The vaccine is expected to be available in the market by the end of 2021



Sinovac Biotech, a leading provider of biopharmaceutical products in China, has received a drug registration approval from the National Medical Product Administration of China (NMPA) for its Sabin strain based inactivated polio vaccine (Vero cells) (sIPV) on July 12, 2021.

The vaccine is expected to be available in the market by the end of 2021. Sinovac had also submitted an application for prequalification (PQ) to the World Health Organization (WHO) in early 2020 and the WHO conducted its on-site inspection in February 2021.

The company's sIPV is approved for use on infants and children aged 2 months and above to prevent poliomyelitis due to infection of types I, II and III polioviruses.

The primary immunization requires 3 doses at least one month apart, beginning at 2 months of age. A booster shot will be given at 18 month of age.

According to the results of phase III clinical trial, no serious or rare adverse events were observed in relation to vaccinations, which indicates the good safety profile of the sIPV vaccine.

Inactivated polio vaccine (IPV) contains no live virus and, thus, carries no risk of emergence from vaccine-derived poliovirus (VDPV) or vaccine-associated paralytic polio (VAPP).